Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Stroli – the shopping trolley reimagined for modern needs. The shopping trolley, often associated with a particular image, is an untapped category ready for innovation. The market is flooded with generic, budget-friendly options that lack charm, with the exception of Rolser, which is pricier and claims the green niche. Stroli steps in as the go-to brand, offering a unique approach, positioning, voice, and eco-friendly credentials. Say goodbye to sore hands and plastic bags – Stroli makes shopping a pleasure with its high-quality, stylish trolley bags designed to enhance your convenience and style
days to go:
Extended
investment:
Withheld
The GP Service is a web and application-based platform that provides private consultations for patients across the UK. The aim is to provide a safe and easy journey for individuals who are looking for private medical treatment at their convenience and at an affordable cost. They have established a connection with over 1600 pharmacies across the UK. They have an excellent 5-star trust pilot rating and also are 1st Private Online Provider which has access to NHS Medical Records. With the proceeds, the company will scale the enterprise offering, increase brand awareness and also launch additional revenue opportunities.
days to go:
Expired
investment:
£907,540
GIBIE combines ancient Indian dying methods with modern weaving technologies to produce sustainable and luxurious homewares. The company argues that the textile industry uses an astonishing 9 trillion gallons of water annually, as well as, releases harmful gases and chemicals in the air and water. GIBIE aims to change this scenario by bringing forth sustainable linen that has superior qualities to chemically enhanced and dyed linen. It has come out with an industrial-scale production proposal of its linen. The company is a PETA-approved vegan brand and a member of the Color Ashram Foundation that promotes the usage of herbal dyes around the world. GIBIE will use the investment to launch its essential sales programs, boost marketing initiatives and scale production.
days to go:
Expired
investment:
£158,571
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
Clinical Net is a health-tech firm focused on revolutionizing access to innovative clinical trials. Their AI platform swiftly connects patients with suitable trials, addressing the challenge of low participation rates and delays that hinder pharmaceutical research. With over 69,000 trials globally, their solution aims to streamline the cumbersome and time-consuming process of trial matching, making it more efficient and accessible within 5 minutes. This innovative approach targets the $3.73 billion patient recruitment market while ensuring individuals have easier access to groundbreaking treatments.
days to go:
Expired
investment:
£136,827
Bazar is the UK’s first dedicated ethical marketplace and lifestyle application. The company intends to disrupt the ~£32.8 billion UK consumer marketplace by creating a platform where eco-friendly businesses can thrive, and consumers can trust brand values. It brings curated ethical and eco-friendly brands, artisans, and items under one portal. BAZAR soft-launched its application with 35 sellers and 650 products in the COVID-19 lockdown which doubled showing positive seller demand. The app saw over 1800 downloads with early sales. The company has a social media presence with over 1500+ Instagram followers. It intends to enter the US market in 2022, followed by Europe. Bazar will use the investment to continue to develop its technology to help sellers grow their business and give buyers an intuitive shopping experience on the app.
days to go:
Expired
investment:
£208,368
White Peak Distillery (WPD) is a whisky distillery that aims to change the way whisky is made and create authentic flavours. It has so far invested £1.4 million in tried and tested plant equipment producing 400,000 bottles of maturing whisky. The company aims to become a contender in the $60 billion global premium whisky market. WPD has received 'Gold Awards' from The Wizards of Whisky World Whisky Awards. It has come out with programs to monetise its maturing whisky including its Cask Sales program, Temperance Club membership and its Prologue 2.1 release 2-year aged single malt spirit, that has been received with positive feedback. WPD has also been awarded visitor business in The Peak District, which receives 13 million+ visitors per annum, boosting its Direct-to-Consumer (D2C) model. It will use the investment to grow its business across different verticals.
days to go:
Expired
investment:
£1,301,320
